Idiopathic Hypersomnia Clinical Trials

16 recruiting

Idiopathic Hypersomnia Trials at a Glance

15 actively recruiting trials for idiopathic hypersomnia are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Huntersville, Winter Park, and Cincinnati. Lead sponsors running idiopathic hypersomnia studies include Centessa Pharmaceuticals (UK) Limited, Alkermes, Inc., and Hospices Civils de Lyon.

Browse idiopathic hypersomnia trials by phase

Treatments under study

About Idiopathic Hypersomnia Clinical Trials

Looking for clinical trials for Idiopathic Hypersomnia? There are currently 16 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Idiopathic Hypersomnia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Idiopathic Hypersomnia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 2

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Idiopathic HypersomniaNarcolepsy Type 1Narcolepsy Type 2
Centessa Pharmaceuticals (UK) Limited248 enrolled37 locationsNCT06752668
Recruiting
Phase 2

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Idiopathic HypersomniaNarcolepsy Type 1Narcolepsy Type 2
Centessa Pharmaceuticals (UK) Limited90 enrolled24 locationsNCT07096674
Recruiting
Phase 3

A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)

Idiopathic Hypersomnia
Harmony Biosciences Management, Inc.248 enrolled12 locationsNCT07500090
Recruiting
Phase 2

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

Idiopathic Hypersomnia
Takeda96 enrolled29 locationsNCT06812078
Recruiting
Phase 2Phase 3

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

Idiopathic HypersomniaNarcolepsy Type 1Narcolepsy Type 2
Alkermes, Inc.256 enrolled46 locationsNCT06767683
Recruiting
Phase 2

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

Idiopathic Hypersomnia
Alkermes, Inc.96 enrolled48 locationsNCT06843590
Recruiting
Not Applicable

A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic Hypersomnia

Idiopathic HypersomniaNarcolepsy Type 1 (NT 1)Narcolepsy Type 2 (NT2)
University of Sydney30 enrolled1 locationNCT07006233
Recruiting
Phase 2

a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial

Idiopathic Hypersomnia
University Hospital, Strasbourg, France72 enrolled1 locationNCT06252571
Recruiting
Phase 4

Low Sodium Oxybate in Patients With Idiopathic Hypersomnia

Idiopathic Hypersomnia
Mayo Clinic30 enrolled4 locationsNCT05837091
Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Rare DisordersUndiagnosed DisordersDisorders of Unknown Prevalence+188 more
Sanford Health20,000 enrolled2 locationsNCT01793168
Recruiting
Not Applicable

Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions

Idiopathic HypersomniaNarcolepsy Type 1Hypersomnolence
Hospices Civils de Lyon180 enrolled1 locationNCT06457945
Recruiting
Not Applicable

Deciphering the Interactions Between Food Intake, Sleepiness, and Nighttime Sleep Quality in Patients With Type 1 Narcolepsy and Idiopathic Hypersomnia

Idiopathic HypersomniaNarcolepsy Type 1
Hospices Civils de Lyon60 enrolled2 locationsNCT06484348
Recruiting
Not Applicable

Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence

Idiopathic HypersomniaNarcolepsyCataplexy
University Hospital, Montpellier117 enrolled1 locationNCT05615584
Recruiting

International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study

Hypersomnolence DisorderIdiopathic HypersomniaNarcolepsy
Insel Gruppe AG, University Hospital Bern600 enrolled1 locationNCT04330963
Recruiting

Mainz Register of Patients With Sleep Disorders

InsomniaIdiopathic HypersomniaSleep Disorder+6 more
Johannes Gutenberg University Mainz500 enrolled1 locationNCT05321355